CN111217873B - 一种倍半萜苷单体化合物及其制备方法与应用 - Google Patents
一种倍半萜苷单体化合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN111217873B CN111217873B CN202010053433.9A CN202010053433A CN111217873B CN 111217873 B CN111217873 B CN 111217873B CN 202010053433 A CN202010053433 A CN 202010053433A CN 111217873 B CN111217873 B CN 111217873B
- Authority
- CN
- China
- Prior art keywords
- sesquiterpene glycoside
- sesquiterpene
- methanol
- monomer compound
- high performance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Sesquiterpene glycoside Chemical class 0.000 title claims abstract description 64
- 229930004725 sesquiterpene Natural products 0.000 title claims abstract description 64
- 229930182470 glycoside Natural products 0.000 title claims abstract description 58
- 150000001875 compounds Chemical class 0.000 title claims abstract description 42
- 239000000178 monomer Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims description 7
- 230000036541 health Effects 0.000 claims abstract description 5
- 239000003472 antidiabetic agent Substances 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 238000004440 column chromatography Methods 0.000 claims description 15
- 238000010828 elution Methods 0.000 claims description 12
- 235000009008 Eriobotrya japonica Nutrition 0.000 claims description 11
- 241001092070 Eriobotrya Species 0.000 claims description 10
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 238000002953 preparative HPLC Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 239000004952 Polyamide Substances 0.000 claims description 5
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 5
- 229920002647 polyamide Polymers 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 238000010829 isocratic elution Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 15
- 239000008103 glucose Substances 0.000 abstract description 14
- 229920002527 Glycogen Polymers 0.000 abstract description 8
- 229940096919 glycogen Drugs 0.000 abstract description 8
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract description 3
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 25
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 5
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 5
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 4
- 235000021314 Palmitic acid Nutrition 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 2
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- FQTLCLSUCSAZDY-UHFFFAOYSA-N (+) E(S) nerolidol Natural products CC(C)=CCCC(C)=CCCC(C)(O)C=C FQTLCLSUCSAZDY-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- FQTLCLSUCSAZDY-ATGUSINASA-N Nerolidol Chemical compound CC(C)=CCC\C(C)=C\CC[C@](C)(O)C=C FQTLCLSUCSAZDY-ATGUSINASA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000004155 insulin signaling pathway Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- WASNIKZYIWZQIP-AWEZNQCLSA-N nerolidol Natural products CC(=CCCC(=CCC[C@@H](O)C=C)C)C WASNIKZYIWZQIP-AWEZNQCLSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种新型倍半萜苷单体化合物及其在制备降血糖药物或保健品方面的应用。该倍半萜苷名称为:橙花叔醇‑3‑O‑α‑L‑吡喃阿拉伯糖基(1→4)‑α‑L‑吡喃鼠李糖基(1→2)‑[α‑L‑吡喃鼠李糖基(1→6)]‑β‑D‑吡喃葡萄糖苷,该倍半萜苷能显著促进人肝癌细胞(HepG2)的葡萄糖消耗,促进糖原合成,具有良好的降血糖活性。
Description
技术领域
本发明涉及中药领域,具体涉及一种天然提取的新型倍半萜苷单体化合物。
背景技术
2型糖尿病是一种慢性代谢性疾病,其特征是胰岛β细胞功能受损以及由于胰岛素信号通路受损而导致的周围组织(例如骨骼肌,脂肪组织和肝脏)对胰岛素敏感性减弱。因此,提高胰岛素敏感性,促进器官组织对葡萄糖的摄取是治疗2型糖尿病重要的切入点。
枇杷叶为蔷薇科植物枇杷〔Eriobotrya japonica(Thunb.)Lindl.〕的干燥叶,在中国分布广泛,是一味常用中药,味苦,性微寒,具有清肺止咳,降逆止呕,抗氧化,抗炎和保肝护肝的功效。用于治疗肺热咳嗽、气逆喘气、胃热呕逆、烦热口渴等症状,符合中医治疗糖尿病“消渴”的范畴。已有的文献报道显示,枇杷叶中含有丰富的具有良好生物活性的化合物,包括多糖、黄酮、多酚、萜类以及其它类型化合物。国内已公开的发明专利(200810018820.8,200810024412.3,200410015695.7,201410802741.1)分别指出了枇杷叶总三萜酸、总黄酮和总倍半萜苷具有抗糖尿病作用。本课题组前期的研究发现,总倍半萜苷具有改善胰岛素抵抗,治疗2型糖尿病的作用,需要进一步研究其中起效的具体成分。
发明内容
本发明的目的是为了提供一种具有降糖活性的新药物或保健食品。
为了实现上述目的,本发明提供了一种倍半萜苷单体化合物,该倍半萜苷单体化合物的化学结构式如下:
上述倍半萜苷单体化合物通过从枇杷叶中提取分离制备。
具体的,该倍半萜苷单体化合物通过以下步骤制备得到:
(1)提取:取干燥枇杷叶,醇提,合并提取液后,减压浓缩至沉淀析出,离心,得上清液;
(2)分离:取上清液,经大孔树脂吸附后,水-乙醇梯度洗脱,收集乙醇浓度为60%-80%的洗脱部分;再经聚酰胺柱层析,水-甲醇梯度洗脱,收集甲醇浓度为0%-20%的洗脱部分;再经反向ODS柱层析,水-甲醇梯度洗脱,收集甲醇浓度为50%-80%的洗脱部分,得总倍半萜苷提取物;
(3)纯化:经步骤(2)中得到的总倍半萜苷提取物经制备型高效液相色谱柱层析进行纯化,的所述倍半萜苷单体化合物。
其中,步骤(3)制备型高效液相色谱柱层析纯化的色谱条件:RP-C18柱,规格为5μm,9.4×250mm,流动相A相为甲醇,B相为水,采用等度洗脱程序:0-40min,65%A,流速为8mL/min,柱温为25℃,检测波长为210nm。
上述制备方法,更为具体的包括以下步骤:
(1)提取:将枇杷叶干燥和粉碎后,按料液比(kg/L)1:6-1:10加入质量百分比浓度为60-100%乙醇室温浸泡提取3次,合并提取液,减压浓缩至有沉淀析出,浓缩液分次离心,速率为2000-4000转/分钟;得上清液;
(2)分离:取上清液,经XAD16大孔树脂吸附,水-乙醇梯度洗脱,高效液相检测分析后合并乙醇浓度为60-80%之间的流分,减压浓缩;浓缩液进一步经聚酰胺柱层析,水-甲醇梯度洗脱,经高效液相检测分析后合并甲醇浓度为0-20%之间的流分,减压浓缩;浓缩液进一步经反向ODS柱层析,水-甲醇梯度洗脱,经高效液相检测分析后合并甲醇浓度为50-80%之间的流分,减压浓缩得到总倍半萜苷提取物。
(3)纯化:将总倍半萜苷提取物经制备型高效液相色谱柱层析进行纯化,得到权利要求1所述化合物。
本发明还提供了上述倍半萜苷单体化合物在制备降血糖药物或保健品方面的应用。
进一步的,该倍半萜苷在制备治疗2型糖尿病药物或保健品方面的应用。
本发明相比现有技术具有以下优点:
本发明通过对枇杷叶总倍半萜中分离提纯得到的倍半萜苷单体化合物的药理研究,明确了其在一定浓度下可以显著促进人肝癌细胞(HepG2)的葡萄糖消耗,促进糖原合成,具有良好的降血糖活性,为后续作为降糖药的药效研究、进一步临床研究及指导用药奠定了基础,拓展了2型糖尿病治疗药物的种类。
附图说明
图1为本发明倍半萜苷单体化合物的结构式;
图2为本发明倍半萜苷单体化合物的1H-NMR谱;
图3为本发明倍半萜苷单体化合物的13C-NMR谱;
图4为本发明倍半萜苷单体化合物的HMBC谱;
图5为本发明倍半萜苷单体化合物的HMQC谱;
图6为本发明倍半萜苷单体化合物的COSY谱;
图7为本发明倍半萜苷单体化合物的NOESY谱;
图8为本发明实例3中倍半萜苷单体化合物对HepG2细胞葡萄糖消耗的影响效果图;
图9为本发明实例4中倍半萜苷单体化合物对HepG2细胞糖原合成的影响效果图。
具体实施方式
下面结合实施例对本发明作进一步详细的描述,但本发明的实施方式不限于此。
实施例1:本发明倍半萜苷单体化合物的制备
取干燥枇杷叶1kg,粉碎,用质量百分比浓度为80%的乙醇溶液10L室温浸泡提取3次,合并提取液,过滤,减压浓缩至有沉淀析出,3000转/分钟离心15分钟,取上清液备用;
将上述上清液缓缓流过XAD16大孔吸附树脂柱,用水-乙醇梯度洗脱,经高效液相检测分析后合并乙醇浓度为60-80%之间的流分,减压浓缩,备用。
上述浓缩液进一步流过经处理后的聚酰胺(200目,200g)柱,用水-甲醇梯度洗脱,经高效液相检测分析后合并甲醇浓度为0-20%之间的流分,减压浓缩,浓缩液进一步经反向ODS柱层析,水-甲醇梯度洗脱,经高效液相检测分析后合并甲醇浓度为50-80%之间的流分,减压浓缩得到总倍半萜苷提取物。将总倍半萜苷提取物上制备型高效液相色谱(岛津LC-6AD)纯化,得到本发明倍半萜苷单体化合物。制备型高效液相色谱条件如下:AgilentRP-C18柱,规格为5μm,9.4×250mm,流动相A相为甲醇,B相为水,采用等度洗脱程序:0-40min,65%A,流速为8mL/min,柱温为25℃,检测波长为210nm。
实施例2:上述倍半萜苷单体化合物的结构解析
实施例1制备得到的化合物为白色粉末,易溶于甲醇。HR-ESI-TOF/MS显示[M-H]-准分子离子m/z 807.5577,确定其分子式为C38H64O18,理化性质和波谱特征表明其为倍半萜苷类化合物。在1H NMR图谱(如表1、图2所示)中,δ5.21(H-1a,1H),5.17(H-1b,1H),5.76(H-2,1H),5.08(H-6,1H)和5.07(H-10,1H)为乙烯基质子信号。单峰δ1.56(H-12,3H)和1.63(H-15,3H)为连接在烯碳上的偕二甲基信号。单峰δ1.54(H-14,3H)对应一个甲基信号,并与双键相连。另一个单峰δ1.27(H-13,3H)也为甲基信号,且与季碳相连。四个多重峰δ1.46(H-4),1.92(H-5),1.94(H-8)和2.01(H-9),都为对应的亚甲基信号。在13C NMR图谱(表1、图3所示)中,δ116.08(C-1),143.44(C-2),124.68(C-6),134.66(C-7),124.61(C-10)和131.05(C-11)对应3对烯碳信号。δ79.98(C-3)为氧取代碳信号。分析以上数据,可知化合物的苷元为橙花叔醇。
在糖信号区域,氧取代的碳信号δ79.98(C-3)表现出低场位移,说明成苷位置在C-3位。此外可看到4个质子信号δ4.25(H-1′,1H),5.13(H-1",1H),4.32(H-1″′,1H),和4.56(H-1″″,1H),其分别与糖的4个异头碳δ96.90(C-1′),100.24(C-1″),106.16(C-1″′)和101.29(C-1″″)相连。通过GC分析衍生化后化合物的单糖,并与对照品比对,可知化合物所含单糖为D-葡萄糖、L-鼠李糖和L-阿拉伯糖(比率为1:2:1)。由葡萄糖端基H的较大耦合常数JH-1′,H-2′(7.6Hz)可以推定葡萄糖为β端基构型,鼠李糖的C-3(δ70.95,71.09)和C-5(δ66.79,68.79)共振信号比对应的β异构体出现在更高场,表明其为α端基构型,而由JH-1″′,H-2″′(7.5Hz)可确定阿拉伯糖也为α端基构型。糖的连接顺序信息可由HMBC谱中相关信号获得:阿拉伯糖的H-1″′(δ4.32)与鼠李糖的C-4″(δ83.72)相关,而鼠李糖的H-1″(δ5.13)又与葡萄糖的C-2′(δ78.47)相关,另一个鼠李糖的H-1″″(δ4.56)与葡萄糖的C-6′(δ67.45)相关,同时葡萄糖的H-1′(δ4.25)与苷元C-3(δ79.98)相关。如图5至图7所示。综合以上信息,化合物鉴定为橙花叔醇-3-O-α-L-吡喃阿拉伯糖基(1→4)-α-L-吡喃鼠李糖基(1→2)-[α-L-吡喃鼠李糖基(1→6)]-β-D-吡喃葡萄糖苷,化学结构式如图1所示。
表1:本发明倍半萜苷化合物1H NMR和13C NMR的数据归属(DMSO-d6,δ,ppm,J/Hz)
实施例3:本发明倍半萜苷单体化合物的体外降血糖活性测定—HepG2细胞葡萄糖消耗测定
细胞培养:人肝癌HepG2细胞购于中科院上海细胞所,以含50U/mL青霉素,50μg/mL链霉素,10%胎牛血清的低糖DMEM培养液在37℃含5%CO2的细胞培养箱中培养。HepG2细胞贴壁生长,待细胞在对数生长期且细胞在70%~80%传代,0.25%胰酶消化,以1:4传代1次,取对数生长期的细胞进行实验。以2×105的密度将细胞接种于96孔板中,置培养箱中培养。
实验方法:HepG2细胞经24h小时贴壁生长后,将空白组(即正常组)培养液换为含10%FBS的低糖DMEM培养液,模型组培养液换为含10%FBS、250μM棕榈酸的低糖DMEM培养液,给药组(即倍半萜苷5μM、倍半萜苷10μM)培养液换为含10%FBS、250μM棕榈酸及本发明倍半萜苷化合物5μM或10μM的低糖DMEM培养液。在培养箱中孵育24h,将培养液移出,用葡萄糖试剂盒测葡萄糖的含量。即葡萄糖的消耗量等于空白孔的葡萄糖含量减去细胞培养液中葡萄糖含量。
实验结果:如图8所示,本发明倍半萜苷化合物在一定浓度下(5μM~10μM)可显著增加HepG2细胞葡萄糖消耗量,给药组与模型组相比有显著性差异(P<0.001)。该结果显示该倍半萜苷化合物具有降低血糖的功能。
实施例4:本发明倍半萜苷化合物的体外降血糖活性测定—HepG2细胞糖原含量测定
细胞培养:人肝癌HepG2细胞购于中科院上海细胞所,以含50U/mL青霉素,50μg/mL链霉素,10%胎牛血清的低糖DMEM培养基在37℃含5%CO2的细胞培养箱中培养。HepG2细胞贴壁生长,待细胞在对数生长期且细胞在70%~80%传代,0.25%胰酶消化,以1:4传代1次,取对数生长期的细胞进行实验。以2×105的密度将细胞接种于6孔板中,置培养箱中培养。
实验方法:HepG2细胞经24h小时贴壁生长后,将空白组(即正常组)培养液换为含10%FBS的低糖DMEM培养液,模型组培养液换为含10%FBS、250μM棕榈酸的低糖DMEM培养液,给药组(即倍半萜苷5μM、倍半萜苷10μM)培养液换为含10%FBS、250μM棕榈酸及本发明倍半萜苷化合物5μM或10μM的低糖DMEM培养液。在培养箱中孵育24h,吸去上清液,用PBS洗2次,0.25%胰酶消化后,收集细胞。加入0.75mL的糖原提取液超声破碎细胞(功率200W,超声3s,间隔10s,重复30次),置于沸水浴中煮沸20min后,冷却,用蒸馏水定容至5mL,混匀,按照糖原含量检测试剂盒说明书(北京索莱宝科技有限公司)测定糖原含量。
实验结果:如图9所示,本发明倍半萜苷化合物在一定浓度下(5μM~10μM)可显著增加HepG2细胞糖原合成,给药组与模型组相比有显著性差异(P<0.01或P<0.001)。该结果显示枇杷叶新颖倍半萜苷化合物具有降低血糖的功能。
Claims (6)
2.权利要求1所述倍半萜苷单体化合物的制备方法,其特征在于,所述倍半萜苷单体化合物通过以下步骤制备得到:
(1)提取:取干燥枇杷叶,醇提,合并提取液后,减压浓缩至沉淀析出,离心,得上清液;
(2)分离:取上清液,经大孔树脂吸附后,水-乙醇梯度洗脱,收集乙醇浓度为60%-80%的洗脱部分;再经聚酰胺柱层析,水-甲醇梯度洗脱,收集甲醇浓度为0%-20%的洗脱部分;再经反向ODS柱层析,水-甲醇梯度洗脱,收集甲醇浓度为50%-80%的洗脱部分,得总倍半萜苷提取物;
(3)纯化:经步骤(2)中得到的总倍半萜苷提取物经制备型高效液相色谱柱层析进行纯化,得所述倍半萜苷单体化合物。
3.根据权利要求2所述倍半萜苷单体化合物的制备方法,其特征在于:所述步骤(3)制备型高效液相色谱柱层析纯化的色谱条件:RP-C18柱,规格为5μm,9.4×250mm,流动相A相为甲醇,B相为水,采用等度洗脱程序:0-40min,65%A,流速为8mL/min,柱温为25℃,检测波长为210nm。
4.根据权利要求2或3所述倍半萜苷单体化合物的制备方法,其特征在于:所述倍半萜苷单体化合物通过以下步骤制备得到:
(1)提取:将枇杷叶干燥和粉碎后,按料液比1:6-1:10加入质量百分比浓度为60-100%乙醇室温浸泡提取3次,合并提取液,减压浓缩至有沉淀析出,浓缩液分次离心,速率为2000-4000转/分钟;得上清液;
(2)分离:取上清液,经XAD16大孔树脂吸附,水-乙醇梯度洗脱,高效液相检测分析后合并乙醇浓度为60-80%之间的流分,减压浓缩;浓缩液进一步经聚酰胺柱层析,水-甲醇梯度洗脱,经高效液相检测分析后合并甲醇浓度为0-20%之间的流分,减压浓缩;浓缩液进一步经反向ODS柱层析,水-甲醇梯度洗脱,经高效液相检测分析后合并甲醇浓度为50-80%之间的流分,减压浓缩得到总倍半萜苷提取物;
(3)纯化:将总倍半萜苷提取物经制备型高效液相色谱柱层析进行纯化,得到所述倍半萜苷单体化合物。
5.权利要求1所述倍半萜苷单体化合物在制备降血糖药物或保健品方面的应用。
6.根据权利要求5所述的应用,其特征在于,所述倍半萜苷在制备治疗2型糖尿病药物或保健品方面的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010053433.9A CN111217873B (zh) | 2020-01-17 | 2020-01-17 | 一种倍半萜苷单体化合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010053433.9A CN111217873B (zh) | 2020-01-17 | 2020-01-17 | 一种倍半萜苷单体化合物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111217873A CN111217873A (zh) | 2020-06-02 |
CN111217873B true CN111217873B (zh) | 2021-02-19 |
Family
ID=70810817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010053433.9A Active CN111217873B (zh) | 2020-01-17 | 2020-01-17 | 一种倍半萜苷单体化合物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111217873B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112110819B (zh) * | 2020-09-30 | 2023-05-12 | 黑龙江省中医药科学院 | 玉米须乙酸乙酯萃取物中的二萜类化合物的萃取方法及应用 |
-
2020
- 2020-01-17 CN CN202010053433.9A patent/CN111217873B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN111217873A (zh) | 2020-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111704544B (zh) | 一种半日花烷型二萜类化合物及其分离方法和应用 | |
CN111217873B (zh) | 一种倍半萜苷单体化合物及其制备方法与应用 | |
CN103130850A (zh) | 一种从油用牡丹籽饼粕中制备芍药苷的方法 | |
CN111440157B (zh) | 同时分离夏佛塔苷、维采宁-2和蜕皮激素的方法及应用 | |
CN109942385B (zh) | 芭蕉根中三个新化合物及提取分离方法 | |
CN115850218B (zh) | 一种乌药烷型倍半萜二聚体及其制备方法与应用 | |
CN108948038B (zh) | 一种新紫檀烷型黄酮类化合物及其用途 | |
CN111228279B (zh) | 一种新型枇杷叶倍半萜苷在减轻肝细胞脂质沉积上的应用 | |
CN113004299B (zh) | 山竹皮中具有降低餐后血糖的呫吨酮类化合物及其提取方法和应用 | |
CN110862463A (zh) | 具有生物活性的紫花苜蓿根部多糖及其硒化改性多糖的制备 | |
CN113698446B (zh) | 马齿苋中一种生物碱类化合物及其提取分离方法 | |
CN106565444B (zh) | 山药地上部分菲类化合物的提取方法及应用 | |
CN114213375A (zh) | 一种倍半萜内酯化合物及其制备方法与应用 | |
CN110467643A (zh) | 从平卧菊三七中提取脑苷脂的方法及脑苷脂的用途 | |
CN112851612A (zh) | 一种从牛蒡叶中提取的具有降低胆固醇活性化合物及其制备方法与应用 | |
CN107281255B (zh) | 刺槐叶活性部位及其制备方法和应用 | |
CN111647031A (zh) | 一类新生物碱及其提取分离方法和应用 | |
CN111484411B (zh) | 艾叶抗炎有效成分的提取方法和应用 | |
CN110117630A (zh) | 一种右旋糖酐蔗糖酶的糖基化应用以及将其用于制备咖啡酸苯乙酯糖苷的方法 | |
CN114736251B (zh) | 金丝皇菊的提取单体皇菊素b及其提取方法和应用 | |
CN112538100B (zh) | 一种从黄柏中提取的具有抗炎活性的异喹啉生物碱苷类化合物及其制备方法与应用 | |
CN113912657B (zh) | 马齿苋中三种吲哚类生物碱及其提取分离方法与用途 | |
CN114702535B (zh) | 粘委陵菜中活性成分及其制备方法和应用 | |
CN112898358B (zh) | 一个从牛蒡叶中提取的具有抗炎活性的新化合物nby-4及其制备方法与应用 | |
CN114292253B (zh) | 伊犁绢蒿中倍半萜类化合物及制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |